Hospital Británico de Buenos Aires - CABA
Desde el año 2000, el Centro de Oncología del Hospital Británico de Buenos Aires es un espacio que combina calidad asistencial en oncología con una visión centrada en el paciente y en la innovación a través de la investigación clínica. Nuestra misión y visión nos impulsa a la mejora continua participando en el desarrollo y aplicación de nuevos tratamientos para los pacientes con diagnóstico de cáncer en nuestro país.Perdriel 74, CABA, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Specializations
Cáncer de mama
Cáncer de pulmón
Cáncer de próstata
Cáncer de vejiga
Cáncer de riñón
Cáncer
Tumores sólidos Cáncer
Enfermedad de Crohn
Bacteriemia por estafilococo aureus Bacteriemia
Leucemia
Colitis ulcerosa
Hipertensión pulmonar
Pan Tumor Cáncer
Hipertensión arterial pulmonar
Melanoma
Enfermedad de Huntington
Artroplastia Reemplazo de rodilla
Miocardiopatía
Nefropatía Enfermedad renal
Enfermedad renal crónica Anemia
Carcinoma hepatocelular Cáncer de hígado
Nefropatía
Colangitis biliar primaria
Our team
Medical staff
Agustín Miguez
Maria Dolores Daneri
Belén Virasoro
Silvina Palmer
Karina Vera
Natalia Roldan
Micalea Conde
Anahí Martinez
María Acevedo
Anahi Martinez
Ernesto Korbenfeld
Luciana Bella Quero
Yamila Chichotky
Maximiliano Romero
Karina Alejandra Vera
Cintia Novas
Luis Colombato
Patricia Delgado
Hernán Trimarchi
Juan Andres de Paula
Nora Fernández
Javier Benavides
Patricia Delgado
Mariana Lopez
Hugo Armando Laborde
Macarena Saenz
Maria Victoria Dolores Mujica
Claudia M. Shanley
Open studies
Lung cancer
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - ABBV-399 - AbbVieSee more
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation - Krascendo 170 - Hoffmann-La RocheSee more
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - TRIDENT-3 - Zai Lab (Shanghai) Co., Ltd.See more
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) - CodeBreaK 202 - AmgenSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) - MK-2870-009 - Merck Sharp & Dohme LLCSee more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer - Krascendo 1 - Hoffmann-La RocheSee more
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab - DeLLphi-305 - AmgenSee more
Breast Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) - VIKTORIA-1 - Celcuity, Inc.See more
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer - OVELIA - Tolmar Inc.See more
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) - CAMBRIA-2 - AstraZenecaSee more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLCSee more
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer - ELEVATE - Stemline Therapeutics, Inc.See more
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) - MK-6482-029 LITESPARK-029 - Merck Sharp & Dohme LLCSee more
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) - DYNASTY-Breast02 - BioNTech SESee more
Colorectal cancer
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait - CCHOWW - Hospital Alemão Oswaldo CruzSee more
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - AmgenSee more
Multiple myeloma
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - Successor-1 - Bristol-Myers SquibbSee more
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide - MonumenTAL-6 - Janssen Research & Development, LLCSee more
Pulmonary hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients - APD811-301 - United TherapeuticsSee more
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) - LIGHTRAY - Merck Sharp & Dohme LLCSee more
Bile Duct Cancer
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement - FOENIX-CCA4 - Taiho Oncology, Inc.See more
Bladder Cancer
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) - IMCODE004 - Hoffmann-La RocheSee more
Cervical cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) - MK-2870-020 - GOG FoundationSee more
Cholangitis
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis - ELFIDENCE - IpsenSee more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Epilepsies
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy - RISE 2 - Biohaven Therapeutics Ltd.See more
Fatty liver/nash
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis - Kowa Research Institute, Inc.See more
Graft versus Host Disease
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. - ROCKnrol-1 - SanofiSee more
Head and neck cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 - AHEAD-MERIT - BioNTech SESee more
Leukemia
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Lupus
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus - TOPAZ-2 - BiogenSee more
Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy - CYPRESS - Theravance BiopharmaSee more
Myelodysplastic Syndromes
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions - ELEMENT-MDS - Bristol-Myers SquibbSee more
Nephropathy
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Ulcerative colitis
Urothelial cancer
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) - Duravelo-2 - BicycleTx LimitedSee more
